Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers generate feline embryonic stem cells
Scientists had previously developed iPS cells, but this is the first time that ESCs have been generated.
Findings could advance regenerative medicine and conservation.

Researchers have succeeded in generating three lines of feline embryonic stem cells (ESCs).

The pioneering study is expected to have benefits for the advancement of feline regenerative medicine, helping both domesticated and wild cats.

ESCs are considered to be key to veterinary regenerative medicine, largely due to their ability to differentiate into various types of cells and be transplanted to heal internal damage. They are also in a near-natural state, similar to induced pluripotent stem (iPS) cells.

However, while feline iPS cells have previously successfully been generated, researchers had never been able to generate ESCs.

The team, from Osaka Metropolitan University, were able to generate the ESCs using lab-grown blastocysts. Scientists performed in vitro fertilisation of feline sperm and oocytes, which had been taken from discarded reproductive organs after sterilisation surgeries.

By isolating the inner cell mass from blastocyst stage embryos, and then culturing them, the researchers successfully generated high-quality feline ESCs. These ESCs can be maintained in an undifferentiated state, before being differentiated into one of three germ layers: endoderm, ectoderm and mesoderm.

This advancement of feline ESC research is expected to support the treatment of intractable diseases, such as chronic kidney disease.

These cells derived from domestic cats are often being used for research into artificial reproductive technologies (ART) for endangered wild cats. These ESCs could be used to create a supply of germ cells for ART research, tackling the germ cell shortage among wild felines.

As well as their benefits for regenerative medicine, ESCs are also beneficial for drug discoveries and in vitro organogenesis studies. Research into feline ESCs may even contribute to the development of regenerative medicine for humans.

Shingo Hatoya, who led the study, said: "Embryonic stem cells are pluripotent cells, so we believe that comparative studies with iPS cells will further promote veterinary regenerative medicine research,

"The successful establishment of feline ES cells in this study can advance veterinary regenerative medicine by enabling comparative studies with feline iPS cells. Moreover, the potential to derive sperm and oocytes from feline ES cells could contribute to the conservation of endangered wild cat species."

The full study can be found in the journal Regenerative Therapy.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.